ICER Atopic Dermatitis Review Prompted By First Biologic

The Institute for Clinical and Economic Review’s assessment of emerging therapies for atopic dermatitis was driven by both excitement and concern from physicians and payers over the anticipated launch of Regeneron/Sanofi’s dupilumab.

The Institute for Clinical and Economic Review (ICER) decision to develop an assessment report on the effectiveness and value of emerging therapies for the treatment of atopic dermatitis was prompted mainly by the anticipated launch of Regeneron Pharmaceuticals Inc./Sanofi’s Dupixent (dupilumab), the first biologic to treat the condition, Chief Scientific Officer Daniel Ollendorf said in an interview.

The non-profit research institute announced plans to assess the atopic dermatitis drug space Oct. 19. Dupixent is pending at FDA for approval for the treatment of atopic dermatitis, with an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By 

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By 

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

More from Therapy Areas

Gilead Ready To Go After Hepatitis D Again

 
• By 

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By 

The UK major's asthma drug gets a key expanded approval.